Search

Your search keyword '"Iaffaldano P."' showing total 34 results

Search Constraints

Start Over You searched for: Author "Iaffaldano P." Remove constraint Author: "Iaffaldano P." Database OpenAIRE Remove constraint Database: OpenAIRE
34 results on '"Iaffaldano P."'

Search Results

1. Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders Register

2. Signs and symptoms of COVID-19 in patients with multiple sclerosis

3. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register

4. Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration

5. Disease modifying therapies and Covid‐19 severity in Multiple Sclerosis

6. Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience

7. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

8. Epstein-Barr-negative MS: a true phenomenon?

9. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

10. Predictors of definite Multiple Sclerosis in patients with pediatric onset first demyelinating clinical attack

11. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

12. Comorbidities affect treatment choice and persistence in RRMS: a real-life multicenter study

13. To switch therapies in RRMS: why and when? A real-life multicentre study

14. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment

15. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone

16. post marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in intereron beta treatment

17. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis

18. Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

20. Autologous hematopoietic stem cell transplantation reduces disability progression in patients with secondary progressive multiple sclerosis: results from the Italian MS Register

21. Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS

22. Comorbidities affect treatment choice and persistence in RRMS: a multicenter study

23. Comparison of disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies Strategies for disease modification

25. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

26. Disability assessment using Google Maps

27. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study

28. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis

29. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

30. Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian population of patients with multiple sclerosis

31. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients with Primary Progressive Multiple Sclerosis

32. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

33. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

34. Serum and CSF N-acetyl aspartate Levels differ in multiple sclerosis and neuromyelitis optica

Catalog

Books, media, physical & digital resources